Alasdair John Coles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alasdair John Coles has a total of 524 co-authors. Here are the top co-authors by number of shared publications:
- James William L Brown
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
11 shared publications - Nick Cunniffe
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK; Cambridge Clinical Vision Laboratory, University of Cambridge, Cambridge, UK
7 shared publications - Joanne Louise Jones
Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
6 shared publications - Krzysztof Selmaj
Department of Neurology and Neurosurgery, University of Warmia and Mazury, 30 Warszawska Street, Olsztyn 10-082, Poland Center of Neurology, Lodz, Poland
6 shared publications - Christopher E. McMurran
Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
5 shared publications Anthony Traboulsee
Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
4 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by Oxford University Press (OUP) in Brain
Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis
Clinically silent MRI lesions occur frequently in people with relapsing-remitting multiple sclerosis (RRMS) despite disease-modifying therapy (DMT). Guidelines only routinely recommend DMT escalation after multiple silent lesions, and adherence is variable. We explored outcomes and the effect of treatment escalation following single and multiple on-treatment silent lesions. This cohort study and emulated target trial used MSBase registry data from 99 clinics in 26 countries between 2007 and 2025. Clinically stable participants receiving any DMT for RRMS with silent lesions versus without silent lesions were compared. Among participants with silent lesions while taking platform or moderate-efficacy DMTs, outcomes following treatment escalation within 6 months versus no treatment escalation (unless a post-MRI clinical event occurred) were compared. The primary outcome was an MS relapse, and the secondary outcome was 6-month confirmed disability worsening. A total of 10 232 participants met inclusion criteria [71.7% female, mean age 41 (standard deviation 11)]. The 2-year cumulative incidence of relapse was 27.8% [95% confidence interval (CI): 25.7%–29.9%] in participants with silent lesions versus 14.3% (95% CI: 13.5%–15.2%) without [adjusted hazard ratio (aHR) 1.76 (95% CI: 1.57–1.97)]. The 2-year cumulative incidence of disability worsening was 13.8% (95% CI: 12.2%–15.5%) in participants with silent lesions versus 11.4% (95% CI: 10.7%–12.2%) without [aHR 1.38 (95% CI: 1.18–1.62)]. Rates of relapse and disability worsening were higher following single and multiple silent lesions versus no silent lesions. The emulated trial included 2264 participants with ≥1 silent lesion on platform or moderate efficacy DMTs, 286 of whom escalated DMT within 6 months following silent lesions. The 4-year cumulative incidence of relapse was lower following treatment escalation [16.8% (95% CI: 12.4%–23.4%)] versus continuation [38.9% (95% CI: 35.8%–42.1%)], aHR 0.34 (95% CI: 0.23–0.47), with similar aHRs following single and multiple silent lesions. The 4-year cumulative incidence of disability worsening was similar following treatment escalation [16.0% (95% CI: 10.8%–22.2%)] versus continuation [17.7% (95% CI: 15.3%–20.1%)], aHR 0.89 (95% CI: 0.56–1.33). People with RRMS with single or multiple on-treatment silent MRI lesions have higher subsequent risks of relapse and disability worsening than people without silent lesions. DMT escalation mitigates the relapse risk, though disability worsening continues at a similar rate over 4 years. Contrary to guidelines, DMT escalation should be considered after single or multiple silent lesions.
- 24 July 2026
- Published by Oxford University Press (OUP) in Brain
Open AccessTreatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis
Clinically silent MRI lesions occur frequently in people with relapsing-remitting multiple sclerosis (RRMS) despite disease-modifying therapy (DMT). Guidelines only routinely recommend DMT escalation after multiple silent lesions, and adherence is variable. We explored outcomes and the effect of treatment escalation following single and multiple on-treatment silent lesions. This cohort study and emulated target trial used MSBase registry data from 99 clinics in 26 countries between 2007 and 2025. Clinically stable participants receiving any DMT for RRMS with silent lesions versus without silent lesions were compared. Among participants with silent lesions while taking platform or moderate-efficacy DMTs, outcomes following treatment escalation within 6 months versus no treatment escalation (unless a post-MRI clinical event occurred) were compared. The primary outcome was an MS relapse, and the secondary outcome was 6-month confirmed disability worsening. A total of 10 232 participants met inclusion criteria [71.7% female, mean age 41 (standard deviation 11)]. The 2-year cumulative incidence of relapse was 27.8% [95% confidence interval (CI): 25.7%–29.9%] in participants with silent lesions versus 14.3% (95% CI: 13.5%–15.2%) without [adjusted hazard ratio (aHR) 1.76 (95% CI: 1.57–1.97)]. The 2-year cumulative incidence of disability worsening was 13.8% (95% CI: 12.2%–15.5%) in participants with silent lesions versus 11.4% (95% CI: 10.7%–12.2%) without [aHR 1.38 (95% CI: 1.18–1.62)]. Rates of relapse and disability worsening were higher following single and multiple silent lesions versus no silent lesions. The emulated trial included 2264 participants with ≥1 silent lesion on platform or moderate efficacy DMTs, 286 of whom escalated DMT within 6 months following silent lesions. The 4-year cumulative incidence of relapse was lower following treatment escalation [16.8% (95% CI: 12.4%–23.4%)] versus continuation [38.9% (95% CI: 35.8%–42.1%)], aHR 0.34 (95% CI: 0.23–0.47), with similar aHRs following single and multiple silent lesions. The 4-year cumulative incidence of disability worsening was similar following treatment escalation [16.0% (95% CI: 10.8%–22.2%)] versus continuation [17.7% (95% CI: 15.3%–20.1%)], aHR 0.89 (95% CI: 0.56–1.33). People with RRMS with single or multiple on-treatment silent MRI lesions have higher subsequent risks of relapse and disability worsening than people without silent lesions. DMT escalation mitigates the relapse risk, though disability worsening continues at a similar rate over 4 years. Contrary to guidelines, DMT escalation should be considered after single or multiple silent lesions.
- Open Access
- 13 May 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (11) , 4035-4051
Low-dose IL-2 fails to expand Tregs after alemtuzumab: insight into impaired immune tolerance in multiple sclerosis
Regulatory T cells (Tregs) are essential to preventing autoimmunity. They depend upon interleukin-2 (IL-2) for optimal function and, due to high expression of the CD25 subunit of the IL-2 receptor, are 10-fold more sensitive to IL-2 than effector T cells (Teffs). Consequently, low-dose IL-2 can be used to expand Tregs preferentially, a therapeutic strategy that has shown promise in a number of autoimmune and inflammatory conditions—including graft-versus-host disease and lupus—where IL-2 driven expansion correlates with improvements in some clinical markers of disease activity. Autoimmunity is a frequent delayed complication of treatment with the lymphocyte-depleting drug alemtuzumab in relapsing-remitting multiple sclerosis (RRMS). Here, using in vitro assays, a pre-clinical mouse model and an experimental medicine study, we investigated whether low-dose IL-2 could selectively expand Tregs in alemtuzumab-treated RRMS patients. Six months after alemtuzumab treatment, the frequency of patient-derived naïve CD4+ Teffs expressing high-affinity IL-2 receptors increased from 30.11% ± 5.09% to 72.88% ± 5.57%, and the density of receptors per cell increased, rendering them six times more sensitive to IL-2 in vitro, at concentrations that typically favour Tregs. Using a human CD52-expressing transgenic mouse model of alemtuzumab treatment, we found that IL-2 could still preferentially expand Tregs, but only when administered at a later time point, corresponding to more than 6 months post-treatment in patients. Guided by these findings, we evaluated low-dose IL-2 for Treg expansion in a prospective open-label mechanistic study of RRMS patients who had received alemtuzumab more than 6 months previously. IL-2, at a dose and frequency similar to that previously shown to expand Tregs in autoimmune diabetes (0.3 × 106 IU/m2 twice a week), was well tolerated and safe, but unexpectedly failed to expand Tregs. We discuss the potential reasons underlying this lack of response, ruling out sIL2RA-related neutralization and instead considering ceiling effects on Treg proliferation, Treg exhaustion and intrinsic Treg dysfunction in MS as possible contributors. Together, our findings demonstrate that low-dose IL-2 alone is not an effective strategy for promoting Treg expansion post-alemtuzumab and is therefore not a viable approach on its own for preventing post-treatment autoimmune complications.
- 13 May 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (11) , 4035-4051
Open AccessLow-dose IL-2 fails to expand Tregs after alemtuzumab: insight into impaired immune tolerance in multiple sclerosis
Regulatory T cells (Tregs) are essential to preventing autoimmunity. They depend upon interleukin-2 (IL-2) for optimal function and, due to high expression of the CD25 subunit of the IL-2 receptor, are 10-fold more sensitive to IL-2 than effector T cells (Teffs). Consequently, low-dose IL-2 can be used to expand Tregs preferentially, a therapeutic strategy that has shown promise in a number of autoimmune and inflammatory conditions—including graft-versus-host disease and lupus—where IL-2 driven expansion correlates with improvements in some clinical markers of disease activity. Autoimmunity is a frequent delayed complication of treatment with the lymphocyte-depleting drug alemtuzumab in relapsing-remitting multiple sclerosis (RRMS). Here, using in vitro assays, a pre-clinical mouse model and an experimental medicine study, we investigated whether low-dose IL-2 could selectively expand Tregs in alemtuzumab-treated RRMS patients. Six months after alemtuzumab treatment, the frequency of patient-derived naïve CD4+ Teffs expressing high-affinity IL-2 receptors increased from 30.11% ± 5.09% to 72.88% ± 5.57%, and the density of receptors per cell increased, rendering them six times more sensitive to IL-2 in vitro, at concentrations that typically favour Tregs. Using a human CD52-expressing transgenic mouse model of alemtuzumab treatment, we found that IL-2 could still preferentially expand Tregs, but only when administered at a later time point, corresponding to more than 6 months post-treatment in patients. Guided by these findings, we evaluated low-dose IL-2 for Treg expansion in a prospective open-label mechanistic study of RRMS patients who had received alemtuzumab more than 6 months previously. IL-2, at a dose and frequency similar to that previously shown to expand Tregs in autoimmune diabetes (0.3 × 106 IU/m2 twice a week), was well tolerated and safe, but unexpectedly failed to expand Tregs. We discuss the potential reasons underlying this lack of response, ruling out sIL2RA-related neutralization and instead considering ceiling effects on Treg proliferation, Treg exhaustion and intrinsic Treg dysfunction in MS as possible contributors. Together, our findings demonstrate that low-dose IL-2 alone is not an effective strategy for promoting Treg expansion post-alemtuzumab and is therefore not a viable approach on its own for preventing post-treatment autoimmune complications.
- Open Access
Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis
Clinically silent MRI lesions occur frequently in people with relapsing-remitting multiple sclerosis (RRMS) despite disease modifying therapy (DMT). Guidelines only recommend DMT escalation after multiple silent lesions, and adherence is variable. We explored outcomes and the effect of treatment escalation following single and multiple on-treatment silent lesions. This cohort study and emulated target trial used MSBase registry data from 99 clinics in 26 countries between 2007 and 2025. Clinically stable participants receiving any DMT for RRMS with silent lesions versus without silent lesions were compared. Among participants with silent lesions while taking platform or moderate-efficacy DMTs, outcomes following treatment escalation within 6 months versus no treatment escalation (unless a post-MRI clinical event occurred) were compared. The primary outcome was an MS relapse, and the secondary outcome was 6-month confirmed disability worsening. A total of 10,232 participants met inclusion criteria (71.7% female, mean age 41 [SD 11]). The 2-year cumulative incidence of relapse was 27.8% (95% CI 25.7%-29.9%) in participants with silent lesions versus 14.3% (95% CI 13.5%-15.2%) without (adjusted hazard ratio [aHR] 1.76 [95% CI 1.57-1.97]). The 2-year cumulative incidence of disability worsening was 13.8% (95% CI 12.2%-15.5%) in participants with silent lesions versus 11.4% (95% CI 10.7%-12.2%) without (aHR 1.38 [95% CI 1.18-1.62]). Rates of relapse and disability worsening were higher following single and multiple silent lesions versus no silent lesions. The emulated trial included 2,264 participants with ≥1 silent lesion on platform or moderate efficacy DMTs, 286 of whom escalated DMT within 6 months following silent lesions. The 4-year cumulative incidence of relapse was lower following treatment escalation (16.8% [95% CI 12.4%-23.4%]) versus continuation (38.9% [95% CI 35.8%-42.1%]), aHR 0.34 (95% CI 0.23-0.47), with similar aHRs following single and multiple silent lesions. The 4-year cumulative incidence of disability worsening was similar following treatment escalation (16.0% [95% CI 10.8%-22.2%]) versus continuation (17.7% [95% CI 15.3%-20.1%]), aHR 0.89 (95% CI 0.56-1.33). People with RRMS with single or multiple on-treatment silent MRI lesions have higher subsequent risks of relapse and disability worsening than people without silent lesions. DMT escalation mitigates the relapse risk, though disability worsening continues at a similar rate over 4 years. Contrary to guidelines, DMT escalation should be considered after single or multiple silent lesions.
Open AccessTreatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis
Clinically silent MRI lesions occur frequently in people with relapsing-remitting multiple sclerosis (RRMS) despite disease modifying therapy (DMT). Guidelines only recommend DMT escalation after multiple silent lesions, and adherence is variable. We explored outcomes and the effect of treatment escalation following single and multiple on-treatment silent lesions. This cohort study and emulated target trial used MSBase registry data from 99 clinics in 26 countries between 2007 and 2025. Clinically stable participants receiving any DMT for RRMS with silent lesions versus without silent lesions were compared. Among participants with silent lesions while taking platform or moderate-efficacy DMTs, outcomes following treatment escalation within 6 months versus no treatment escalation (unless a post-MRI clinical event occurred) were compared. The primary outcome was an MS relapse, and the secondary outcome was 6-month confirmed disability worsening. A total of 10,232 participants met inclusion criteria (71.7% female, mean age 41 [SD 11]). The 2-year cumulative incidence of relapse was 27.8% (95% CI 25.7%-29.9%) in participants with silent lesions versus 14.3% (95% CI 13.5%-15.2%) without (adjusted hazard ratio [aHR] 1.76 [95% CI 1.57-1.97]). The 2-year cumulative incidence of disability worsening was 13.8% (95% CI 12.2%-15.5%) in participants with silent lesions versus 11.4% (95% CI 10.7%-12.2%) without (aHR 1.38 [95% CI 1.18-1.62]). Rates of relapse and disability worsening were higher following single and multiple silent lesions versus no silent lesions. The emulated trial included 2,264 participants with ≥1 silent lesion on platform or moderate efficacy DMTs, 286 of whom escalated DMT within 6 months following silent lesions. The 4-year cumulative incidence of relapse was lower following treatment escalation (16.8% [95% CI 12.4%-23.4%]) versus continuation (38.9% [95% CI 35.8%-42.1%]), aHR 0.34 (95% CI 0.23-0.47), with similar aHRs following single and multiple silent lesions. The 4-year cumulative incidence of disability worsening was similar following treatment escalation (16.0% [95% CI 10.8%-22.2%]) versus continuation (17.7% [95% CI 15.3%-20.1%]), aHR 0.89 (95% CI 0.56-1.33). People with RRMS with single or multiple on-treatment silent MRI lesions have higher subsequent risks of relapse and disability worsening than people without silent lesions. DMT escalation mitigates the relapse risk, though disability worsening continues at a similar rate over 4 years. Contrary to guidelines, DMT escalation should be considered after single or multiple silent lesions.
- Open Access
- 8 December 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 562
The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy
Background: In multiple sclerosis (MS), progressive disability occurs following degeneration of demyelinated axons. A tractable approach to delay, prevent or reverse disability progression is through enhancement of endogenous remyelination. Clinical trials have deployed drugs, such as clemastine, to target the rate-limiting step in this process: differentiation of oligodendrocyte progenitor cells (OPCs). Preclinical research has shown that metformin can reverse an age-associated deficit in the responsiveness of OPCs to pro-differentiation factors. The purpose of the Cambridge Centre for Myelin Repair trial Two (CCMR Two) is to evaluate the efficacy of the combination of metformin and clemastine to promote remyelination in people with MS. Methods: Participants with relapsing-remitting MS (RRMS) will be randomised 1:1 to the combination of metformin and clemastine or matched placebos and followed for 24 weeks of treatment. All participants must be stable on a disease-modifying therapy and have evidence of chronic stable optic neuropathy in at least one eye (defined by P100 latency of the visual evoked potential (VEP) ≥ 118 ms, and the absence of a history of acute optic neuritis in the preceding 2 years). The primary outcome measure will be the change in the P100 latency of the full-field VEP between baseline and week 26. It is planned to recruit a total of 70 participants. This will have 80% power to detect a reduction of 3 ms in VEP P100 latency between the two treatment groups. Secondary outcome measures will examine the change in multifocal VEP and the change in lesional magnetisation transfer ratio (MTR) for lesions stratified by location and tissue-specific cohort baseline lesional MTR values. Discussion: We set out the trial design, the rationale for participant and outcome measure selection, and the pre-specified analyses. With this trial, we expect to be able to detect the structural and functional consequences of remyelination within a sample size feasible for our single-centre trial. Trial registration: ClinicalTrials.gov NCT05131828, prior to participant enrolment.
- 8 December 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 562
Open AccessThe Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy
Background: In multiple sclerosis (MS), progressive disability occurs following degeneration of demyelinated axons. A tractable approach to delay, prevent or reverse disability progression is through enhancement of endogenous remyelination. Clinical trials have deployed drugs, such as clemastine, to target the rate-limiting step in this process: differentiation of oligodendrocyte progenitor cells (OPCs). Preclinical research has shown that metformin can reverse an age-associated deficit in the responsiveness of OPCs to pro-differentiation factors. The purpose of the Cambridge Centre for Myelin Repair trial Two (CCMR Two) is to evaluate the efficacy of the combination of metformin and clemastine to promote remyelination in people with MS. Methods: Participants with relapsing-remitting MS (RRMS) will be randomised 1:1 to the combination of metformin and clemastine or matched placebos and followed for 24 weeks of treatment. All participants must be stable on a disease-modifying therapy and have evidence of chronic stable optic neuropathy in at least one eye (defined by P100 latency of the visual evoked potential (VEP) ≥ 118 ms, and the absence of a history of acute optic neuritis in the preceding 2 years). The primary outcome measure will be the change in the P100 latency of the full-field VEP between baseline and week 26. It is planned to recruit a total of 70 participants. This will have 80% power to detect a reduction of 3 ms in VEP P100 latency between the two treatment groups. Secondary outcome measures will examine the change in multifocal VEP and the change in lesional magnetisation transfer ratio (MTR) for lesions stratified by location and tissue-specific cohort baseline lesional MTR values. Discussion: We set out the trial design, the rationale for participant and outcome measure selection, and the pre-specified analyses. With this trial, we expect to be able to detect the structural and functional consequences of remyelination within a sample size feasible for our single-centre trial. Trial registration: ClinicalTrials.gov NCT05131828, prior to participant enrolment.
- Open Access
- 6 October 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (1) , 48-58
Ageing and remyelination failure in people with multiple sclerosis
One of the most promising strategies to delay, prevent, or reverse disability progression in multiple sclerosis is enhancing endogenous remyelination. While preclinical research has established a strong connection between ageing and remyelination failure, evidence for this same link in people with multiple sclerosis remains less secure. As clinical trials for remyelinating therapies progress, clarifying this relationship is essential. A deeper understanding could guide the selection of therapeutic candidates, refine patient selection, and optimize the timing of treatment delivery. In this review, we describe the available evidence that has investigated the impact of age on remyelination in people with multiple sclerosis. We categorize these into pathological, imaging and clinical studies. We explore the challenges in measuring remyelination in humans and determine the implications for the connection between remyelination and age. Current evidence suggests that there is reduced capacity for remyelination with advancing age in people with multiple sclerosis. However, these findings are at times inconsistent, and the precise contribution of ageing to remyelination failure is unclear. There does not appear to be an age cut-off beyond which remyelination is not possible, as there are pathological data supporting remyelination occurring, to some extent, across all ages. Interestingly, the impact of age may vary by lesion location. Further targeted research, specifically exploring the relationship between ageing and remyelination, is needed. With emerging evidence that ageing processes might be malleable, we conclude that targeting the biology of ageing might also be an important strategy to therapeutically enhance remyelination.
- 6 October 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (1) , 48-58
Open AccessAgeing and remyelination failure in people with multiple sclerosis
One of the most promising strategies to delay, prevent, or reverse disability progression in multiple sclerosis is enhancing endogenous remyelination. While preclinical research has established a strong connection between ageing and remyelination failure, evidence for this same link in people with multiple sclerosis remains less secure. As clinical trials for remyelinating therapies progress, clarifying this relationship is essential. A deeper understanding could guide the selection of therapeutic candidates, refine patient selection, and optimize the timing of treatment delivery. In this review, we describe the available evidence that has investigated the impact of age on remyelination in people with multiple sclerosis. We categorize these into pathological, imaging and clinical studies. We explore the challenges in measuring remyelination in humans and determine the implications for the connection between remyelination and age. Current evidence suggests that there is reduced capacity for remyelination with advancing age in people with multiple sclerosis. However, these findings are at times inconsistent, and the precise contribution of ageing to remyelination failure is unclear. There does not appear to be an age cut-off beyond which remyelination is not possible, as there are pathological data supporting remyelination occurring, to some extent, across all ages. Interestingly, the impact of age may vary by lesion location. Further targeted research, specifically exploring the relationship between ageing and remyelination, is needed. With emerging evidence that ageing processes might be malleable, we conclude that targeting the biology of ageing might also be an important strategy to therapeutically enhance remyelination.
- 14 September 2025
- Published by BMJ in Practical Neurology
- Vol. 26 (2) , 104-105
Biosimilar rollouts: practice, pitfalls and the importance of effective communication
- 14 September 2025
- Published by BMJ in Practical Neurology
- Vol. 26 (2) , 104-105
Biosimilar rollouts: practice, pitfalls and the importance of effective communication
- 4 August 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (3) , 951-962
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis
In the treatment of relapsing-remitting multiple sclerosis, autologous haematopoietic stem cell transplant (AHSCT) and immune-reconstitution therapies show several similarities. These treatment strategies have not yet been compared head-to-head. This study emulated pairwise trials of comparative effectiveness of stem cell transplant versus immune-reconstitution therapies cladribine and alemtuzumab. This cohort/registry study of comparative treatment effectiveness included data from seven specialist multiple sclerosis centres with AHSCT programmes (RESCUE-MS) and international MSBase registry during 2006–2023. The study included patients with relapsing-remitting multiple sclerosis treated with AHSCT, cladribine or alemtuzumab, with a minimum of 2-months follow-up before commencing study therapy and ≥2 disability assessments after commencing the study therapy. Patients were matched on a propensity score derived from their clinical and demographic characteristics. The matched groups were compared according to annualized relapse rates, freedom from relapses and 6-month confirmed disability worsening and improvement (measured with the Expanded Disability Status Scale). The matching of 143 (stem cell) to 283 cladribine-treated patients and 134 (stem cell) to 562 alemtuzumab-treated patients reduced the measured differences between the groups by 98% and 96%, respectively. The matched patients had high mean disease activity (>0.8 relapses in the prior 2 years), mean Expanded Disability Status Scale scores of 3–4, and were followed-up for a mean of 3.8–3.9 (stem cell), 1.9 (cladribine) or 4.5 years (alemtuzumab). Compared with cladribine, stem cell transplant was associated with a lower risk of relapse [mean annualized relapse rate ± standard deviation (SD): 0.05 ± 0.28 versus 0.16 ± 0.39, respectively; hazard ratio: 0.24; 95% confidence interval (CI): 0.15–0.41], similar risk of disability worsening (hazard ratio: 0.70; 95% CI: 0.34–1.43) and higher probability of disability improvement (hazard ratio: 2.19; 95% CI: 1.31–3.66). Compared with alemtuzumab, stem cell transplant was associated with a lower risk of relapses (mean annualized relapse rate ± SD: 0.04 ± 0.23 versus 0.09 ± 0.21, respectively; hazard ratio: 0.52; 95% CI: 0.29–0.93), similar risk of disability worsening (hazard ratio: 0.95; 95% CI: 0.53–1.72) and higher probability of disability improvement (hazard ratio: 2.03; 95% CI: 1.23–3.34). Thirty-four per cent of patients treated with stem cell transplant experienced delayed complications, mainly infections. No treatment-associated deaths were reported. Among patients with active relapsing-remitting multiple sclerosis and moderate disability, AHSCT is superior to cladribine and alemtuzumab at suppressing relapses and enabling recovery of neurological function. The high effectiveness of stem cell transplant is likely attributable to a complex interplay between immune suppression and reconstitution.
- 4 August 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (3) , 951-962
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis
In the treatment of relapsing-remitting multiple sclerosis, autologous haematopoietic stem cell transplant (AHSCT) and immune-reconstitution therapies show several similarities. These treatment strategies have not yet been compared head-to-head. This study emulated pairwise trials of comparative effectiveness of stem cell transplant versus immune-reconstitution therapies cladribine and alemtuzumab. This cohort/registry study of comparative treatment effectiveness included data from seven specialist multiple sclerosis centres with AHSCT programmes (RESCUE-MS) and international MSBase registry during 2006–2023. The study included patients with relapsing-remitting multiple sclerosis treated with AHSCT, cladribine or alemtuzumab, with a minimum of 2-months follow-up before commencing study therapy and ≥2 disability assessments after commencing the study therapy. Patients were matched on a propensity score derived from their clinical and demographic characteristics. The matched groups were compared according to annualized relapse rates, freedom from relapses and 6-month confirmed disability worsening and improvement (measured with the Expanded Disability Status Scale). The matching of 143 (stem cell) to 283 cladribine-treated patients and 134 (stem cell) to 562 alemtuzumab-treated patients reduced the measured differences between the groups by 98% and 96%, respectively. The matched patients had high mean disease activity (>0.8 relapses in the prior 2 years), mean Expanded Disability Status Scale scores of 3–4, and were followed-up for a mean of 3.8–3.9 (stem cell), 1.9 (cladribine) or 4.5 years (alemtuzumab). Compared with cladribine, stem cell transplant was associated with a lower risk of relapse [mean annualized relapse rate ± standard deviation (SD): 0.05 ± 0.28 versus 0.16 ± 0.39, respectively; hazard ratio: 0.24; 95% confidence interval (CI): 0.15–0.41], similar risk of disability worsening (hazard ratio: 0.70; 95% CI: 0.34–1.43) and higher probability of disability improvement (hazard ratio: 2.19; 95% CI: 1.31–3.66). Compared with alemtuzumab, stem cell transplant was associated with a lower risk of relapses (mean annualized relapse rate ± SD: 0.04 ± 0.23 versus 0.09 ± 0.21, respectively; hazard ratio: 0.52; 95% CI: 0.29–0.93), similar risk of disability worsening (hazard ratio: 0.95; 95% CI: 0.53–1.72) and higher probability of disability improvement (hazard ratio: 2.03; 95% CI: 1.23–3.34). Thirty-four per cent of patients treated with stem cell transplant experienced delayed complications, mainly infections. No treatment-associated deaths were reported. Among patients with active relapsing-remitting multiple sclerosis and moderate disability, AHSCT is superior to cladribine and alemtuzumab at suppressing relapses and enabling recovery of neurological function. The high effectiveness of stem cell transplant is likely attributable to a complex interplay between immune suppression and reconstitution.
- Open Access
- 27 July 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 103, 106655
Serum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis
- 27 July 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 103, 106655
Open AccessSerum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis
- Open Access
- 27 January 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (4) , 686-700
An MRI assessment of mechanisms underlying lesion growth and shrinkage in multiple sclerosis
Objective: To assess the pathological mechanisms contributing to white matter (WM) lesion expansion or contraction and remyelination in multiple sclerosis (MS).Methods: We assessed 1,613 lesions in 49 people with relapsing–remitting MS in the CCMR‐One bexarotene trial (EudraCT 2014‐003145‐99). We measured lesion orientation relative to WM tracts, surface‐in gradients and veins. Jacobian deformation was used to assess lesion expansion over 6 months, while magnetization transfer ratio (MTR) imaging was used to assess remyelination.Results: At baseline, 33% of lesions were aligned with veins, 2% along WM tracts, 0% with surface‐in gradients, and 4% orthogonal to veins. No significant differences were observed in lesion shape, while lesions aligned with surface‐in gradients and with veins had lower volume compared to all remaining orientations. At follow‐up, 13% of lesions expanded and 7% contracted. The directions for both expansion and contraction were 18% and 8%, respectively, along WM tracts, 20% and 15% parallel to veins, 22% and 23% orthogonal to veins and 0% and 1% along surface‐in gradients. Bexarotene had no effect on lesion expansion or contraction, but MTR significantly increased in lesions aligned with surface‐in gradients and veins.Interpretation: Lesion expansion and shrinkage are affected by venous and WM tract factors, but these do not influence bexarotene's capacity to promote remyelination. This, instead, appears to be affected by surface‐in factors. To limit lesion expansion and maximize tissue repair, multiple processes may need to be targeted.
- 27 January 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (4) , 686-700
Open AccessAn MRI assessment of mechanisms underlying lesion growth and shrinkage in multiple sclerosis
Objective: To assess the pathological mechanisms contributing to white matter (WM) lesion expansion or contraction and remyelination in multiple sclerosis (MS).Methods: We assessed 1,613 lesions in 49 people with relapsing–remitting MS in the CCMR‐One bexarotene trial (EudraCT 2014‐003145‐99). We measured lesion orientation relative to WM tracts, surface‐in gradients and veins. Jacobian deformation was used to assess lesion expansion over 6 months, while magnetization transfer ratio (MTR) imaging was used to assess remyelination.Results: At baseline, 33% of lesions were aligned with veins, 2% along WM tracts, 0% with surface‐in gradients, and 4% orthogonal to veins. No significant differences were observed in lesion shape, while lesions aligned with surface‐in gradients and with veins had lower volume compared to all remaining orientations. At follow‐up, 13% of lesions expanded and 7% contracted. The directions for both expansion and contraction were 18% and 8%, respectively, along WM tracts, 20% and 15% parallel to veins, 22% and 23% orthogonal to veins and 0% and 1% along surface‐in gradients. Bexarotene had no effect on lesion expansion or contraction, but MTR significantly increased in lesions aligned with surface‐in gradients and veins.Interpretation: Lesion expansion and shrinkage are affected by venous and WM tract factors, but these do not influence bexarotene's capacity to promote remyelination. This, instead, appears to be affected by surface‐in factors. To limit lesion expansion and maximize tissue repair, multiple processes may need to be targeted.
- Open Access
- 24 December 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (1) , fcaf032
Exploratory analysis of biological age measures in a remyelination clinical trial
Enhancing CNS myelin repair (remyelination) is a promising strategy to prevent neurodegeneration and associated progressive disability in multiple sclerosis. Remyelination becomes inefficient with older chronological age, but the relationship between measures of biological age and remyelination has not been previously described in a clinical cohort. Here, we investigated two measures of biological age amongst participants of the Cambridge Centre for Myelin Repair One trial of bexarotene: MRI brain age (BAMRI) and a blood-based biological age (BABlood). In people with radiologically stable multiple sclerosis (n = 44 of 49 total participants), we found that treatment with bexarotene, along with promoting remyelination, was associated with significant decrease in MRI brain age [−1.98 years, 95% confidence interval (CI) [−3.75, −0.21 years] versus placebo over 6 months, P = 0.034]. Whilst BAMRI increased as expected during the trial in the placebo group (+0.92 years, CI [−0.41, 2.26]), the brain MRIs of participants treated with bexarotene appeared on average 11 months younger at the end compared to the start of the trial (−0.93 years, CI [−2.02, 0.17]). The effect of bexarotene on BAMRI was associated with its remyelinating activity in cortical grey matter lesions (β = 0.25% units (pu)/year, CI [0.03, 0.46], P = 0.023) and brainstem lesions (β = 0.24 pu/year, CI [0.09, 0.39], P = 0.003). We also observed some regional trends that the remyelinating response to bexarotene was linked with measures of biological age at baseline. For example, after adjustment for chronological age, remyelination of brainstem lesions assessed by magnetization transfer ratio was reduced by 0.06 pu for each year increase in BAMRI (CI [0.00, 0.13], P = 0.058) and 0.02 pu for each year increase in BABlood (CI [−0.01, 0.05], P = 0.17). This is, to the best of our knowledge, the first demonstration that MRI brain age can be therapeutically modulated by a drug in people with a neurological disorder. Overall, these findings highlight that beyond chronological age, biological age may also influence the potential for repair and should be considered when developing treatments for multiple sclerosis.
- 24 December 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (1) , fcaf032
Open AccessExploratory analysis of biological age measures in a remyelination clinical trial
Enhancing CNS myelin repair (remyelination) is a promising strategy to prevent neurodegeneration and associated progressive disability in multiple sclerosis. Remyelination becomes inefficient with older chronological age, but the relationship between measures of biological age and remyelination has not been previously described in a clinical cohort. Here, we investigated two measures of biological age amongst participants of the Cambridge Centre for Myelin Repair One trial of bexarotene: MRI brain age (BAMRI) and a blood-based biological age (BABlood). In people with radiologically stable multiple sclerosis (n = 44 of 49 total participants), we found that treatment with bexarotene, along with promoting remyelination, was associated with significant decrease in MRI brain age [−1.98 years, 95% confidence interval (CI) [−3.75, −0.21 years] versus placebo over 6 months, P = 0.034]. Whilst BAMRI increased as expected during the trial in the placebo group (+0.92 years, CI [−0.41, 2.26]), the brain MRIs of participants treated with bexarotene appeared on average 11 months younger at the end compared to the start of the trial (−0.93 years, CI [−2.02, 0.17]). The effect of bexarotene on BAMRI was associated with its remyelinating activity in cortical grey matter lesions (β = 0.25% units (pu)/year, CI [0.03, 0.46], P = 0.023) and brainstem lesions (β = 0.24 pu/year, CI [0.09, 0.39], P = 0.003). We also observed some regional trends that the remyelinating response to bexarotene was linked with measures of biological age at baseline. For example, after adjustment for chronological age, remyelination of brainstem lesions assessed by magnetization transfer ratio was reduced by 0.06 pu for each year increase in BAMRI (CI [0.00, 0.13], P = 0.058) and 0.02 pu for each year increase in BABlood (CI [−0.01, 0.05], P = 0.17). This is, to the best of our knowledge, the first demonstration that MRI brain age can be therapeutically modulated by a drug in people with a neurological disorder. Overall, these findings highlight that beyond chronological age, biological age may also influence the potential for repair and should be considered when developing treatments for multiple sclerosis.